Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 28,028 | 12,862 |
| Amortization of acquired intangible assets | 11,581 | 3,798 |
| Research and development | 100,873 | 108,973 |
| Selling, general and administrative | 86,183 | 80,961 |
| Change in the fair value of contingent consideration | — | (800) |
| Tangible asset impairment and losses on transactions, net | 927 | 77 |
| Total operating expenses | 227,592 | 205,871 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's R&D?
- PTC Therapeutics (PTCT) reported R&D of $100.87M in Q1 2026.
- How has PTC Therapeutics's R&D changed year-over-year?
- PTC Therapeutics's R&D decreased by 7.4% year-over-year, from $108.97M to $100.87M.
- What is the long-term trend for PTC Therapeutics's R&D?
- Over 4 years (2021 to 2025), PTC Therapeutics's R&D has grown at a -4.2% compound annual growth rate (CAGR), from $540.68M to $455.25M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about PTC Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude